Scientific Presentations & Conferences

Paris Hepatology Conference 2023

APASL 2023

Posters

• Safety, Tolerability and Pharmacokinetics (PK) of Single Ascending Doses of ALG-125755, a GalNAc-Conjugated Small Interfering RNA (siRNA), in Healthy Volunteers (HV)
• ALG-000184, an Orally Administered Capsid Assembly Modulator (CAM) Reduces HBsAg in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)
• Discovery of a Liver-Targeted PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer
• Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia
• Preclinical Antiviral, Pharmacological and Toxicological Characteristics of ALG-000184, a Prodrug of the Novel HBV Capsid Assembly Modulator ALG‑001075

Oral Presentations

• The Capsid Assembly Modulator ALG-000184 Dosed for 28 Days Was Well Tolerated and Rapidly Reduced Viral Markers in Subjects with Chronic Hepatitis B, Including HBsAg in a Subset of HBeAg Positive Subjects with Elevated Baseline ALT
• Preclinical Profile of ALG-125755, a GalNAc-siRNA Targeting HBV
• ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B infection

Respi DART 2022

• Preclinical Evaluation of ALG-097558:A Novel, Orally Bioavailable Pan-Coronavirus 3CLpro Inhibitor for the Treatment of COVID-19

ACT 2022

• The Prodrug of a Novel Capsid Assembly Modulator (CAM), ALG-000184, Demonstrates a Favorable Nonclinical Toxicokinetic and Toxicology Profile for the Treatment of Chronic Hepatitis B (CHB)
• Lack of Translation of Favorable Nonclinical Toxicology Profile of Antisense Oligonucleotide (ASO) ALG-020572 to Chronic Hepatitis B (CHB) Patients
• Prediction of In Vivo Toxicity and Clinical Effects Using Antisense Oligonucleotides in an In Vitro Model Utilizing 3D Insight Human Liver Microtissues

AASLD 2022

• Discovery of Liver-targeted Oral PD-L1 Small Molecule Inhibitors for the Treatment of Chronic Hepatitis B and Liver Cancers
• Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)
• Safety and Tolerability of Multiple Doses of ALG-020572, a GalNAc-conjugated Antisense Oligonucleotide, in Chronic Hepatitis B Subjects
• SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ASCENDING ORAL DOSES OF ALG-055009, A THYROID HORMONE RECEPTOR BETA AGONIST, IN HYPERLIPIDAEMIC SUBJECTS
• Nonclinical efficacy, pharmacokinetic profile and pharmacokinetic/pharmacodynamic (PK/PD) correlation of ALG 125755, a GalNAc conjugated siRNA, for functional cure of chronic hepatitis B
• HAP Class I Capsid Assembly Modulators Clear Hepatitis B Virus-Infected Hepatocytes Through Core-dependent Hepatocyte Death and Subsequent Proliferation
• Non-HAP class I capsid assembly modulators have distinct profiles and a differentiated mechanism of action
• Suppression of PD-L1 expression by a novel liver-targeted siRNA leads to potential restoration of immune responses against HBV

Keystone Symposium 2022

• SARS-CoV-2 Viruses with Cross-Resistance to 3CLpro Inhibitors can be Selected In Vitro, and can Replicate and Transmit in a Hamster Model
• Discovery of ALG-097558, a Novel 3CL Protease Inhibitor with Activity in the SARS-CoV-2 Hamster Infection Model

DOT 2022

• Oral 3CL-Protease Inhibitors for Treating Coronaviral Infections

OPTIONS XI 2022

• Discovery and Antiviral Activity of the Novel 3CL Protease Inhibitor ALG-097558 in the SARS-CoV-2 Hamster Infection Model

IS3NA / IRT 2022

• Oligonucleotide Based Approaches to the Treatment of Chronic Hepatitis B

EASL 2022

• Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B
• Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia
• Safety, Pharmacokinetics, and Antiviral Activity of the Class II Capsid Assembly Modulator ALG-000184 in Subjects with Chronic Hepatitis B
• Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of ALG-020572, a GalNAc Conjugated Antisense Oligonucleotide, in Healthy Subjects
• Safety, Pharmacokinetics, and Antiviral Activity of the S-Antigen Transport Inhibiting Oligonucleotide Polymers (STOPSTM) Drug Candidate ALG-010133 in Subjects with Chronic Hepatitis B
• Incorporation of novel siRNA chemistries significantly improves the potency and durability of HBV siRNAs in the AAV-HBV mouse model
• The HBV siRNA, ALG-125755, demonstrates a favorable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model

APASL 2022

• Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Asian and non-Asian Subjects with Chronic Hepatitis B (CHB)
• Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG
  000184 in Asian and non Asian Subjects with Chronic Hepatitis B (CHB)
• Hepatitis B Surface Antigen (HBsAg) is Significantly Reduced by the HBV small interfering RNA (siRNA) ALG 125755 in HBV Infected Cells and the AAV HBV Mouse Model

SOT 2022

• THE S-ANTIGEN TRANSPORT-INHIBITING OLIGONUCLEOTIDE POLYMER (STOPS™) ALG-010133 DEMONSTRATES A FAVORABLE NONCLINICAL PHARMACOKINETIC AND TOXICOLOGY PROFILE FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB)

ICAR 2022

• Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development
• Mutations L50F, E166A and L167F in SARS-CoV-2 3CLpro are Selected by a Protease Inhibitor In Vitro and are Associated with Resistance
• Discovery of Highly Potent Oligonucleotides Targeting SARS-CoV-2

HEP DART 2021

• Combination Approaches Towards a Functional Cure for Chronic Hepatitis B

AASLD 2021

Chronic Hepatitis B

S-antigen Transport-inhibiting Oligonucleotide Polymers(STOPS^TM)

• S-antigen Transport-inhibiting Oligonucleotide Polymers, (STOPS^TM) Sequester Cellular Proteins to Reduce Hepatitis B Virus S-Antigen Expression and Increase Its Proteasomal Degradation

Capsid Assembly Modulator (CAM)

• Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with Chronic Hepatitis B (CHB)

Antisense Oligonucleotide (ASO)

• Best-in-Class Antisense Oligonucleotides Against Hepatitis B Virus: Next Generation Bridged Nucleic Acid Chemistries Significantly Increase In Vivo Efficacy and Reduce Hepatotoxicity in Mice
• ALG-020572, a GalNAc-Conjugated Antisense Oligonucleotide, Demonstrates In Vivo Efficacy and Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B

siRNA

• Incorporation of Novel siRNA Chemistries Significantly Improves the Potency and Durability of HBV siRNAs in the AAV-HBV Mouse Model

Combinations

• Triple Combination of Anti-Hepatitis B Virus Drugs Demonstrates Synergistic Activity In Vitro

NASH

• Preclinical Pharmacokinetic Profiling of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of Nonalcoholic Steatohepatitis, and Prediction of its Human Pharmacokinetics
• Development of a Novel Seven-Day Dosing Mouse Efficacy Model to Evaluate Thyroid Hormone Receptor Agonists for the Treatment of NASH

Others

• Improved Liver Concentration and Activity of S-antigen Transport-Inhibiting Oligonucleotide Polymers
• ALG-005398 is a Potent Non-HAP Class I HBV Capsid Assembly Modulator that Strongly Reduces HBsAg Levels In Vivo

EASL 2021

• ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model
• Combination drug interactions of hepatitis B virus ( HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo
• Mechanism of Action of HBV S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPSTM) Molecules
• Capsid Assembly Modulator ALG-000111 and its Prodrug ALG-000286 Display Excellent In Vitro and In Vivo Antiviral Activity
• Safety, Tolerability and Pharmacokinetics (PK) of Single and Multiple Doses of ALG-010133, an S-antigen Transport Inhibiting Oligonucleotide Polymer (STOPSTM), for the Treatment of Chronic Hepatitis B

HBV-TAG 2021

• Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity of Multiple Doses of ALG-000184 in Healthy Volunteers (HV) and Subjects with Chronic Hepatitis B (CHB)

CROI 2021

• CROI 2021

APASL 2021

RespiDART 2020

AASLD 2020

EASL 2020

• ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B
• Best in class hepatitis B virus anti sense oligonucleotides Next generation bridged nucleic acid chemistries significantly improve the therapeutic index by reducing hepatotoxicity
• Molecular, cellular and pharmacological characterization of beta selective partial agonists of human thyroid hormone receptor for the treatment of nonalcoholic steatohepatitis
• Combination drug interactions of hepatitis (HBV) S-antigen Transport-inhibiting oligonucleotide polymers in vitro
• Structural requirements for S-antigen Transport-inhibiting oligonucleotide polymer inhibition of hepatitis B surface antigen secretion